

Claims

Please substitute the following claim set for that currently under examination.

1-25. (Cancelled)

26. (Currently amended) ~~The method of claim 22~~ A method of inducing a T-cell response to a tumor which overexpresses mesothelin relative to normal tissue from which it is derived, said method comprising:

administering to a patient who has said tumor or who has had said tumor removed, a composition comprising a *Listeria monocytogenes* bacterium which expresses a polypeptide comprising an MHC Class I-binding epitope of mesothelin, wherein the epitope binds to an allelic form of MHC class I which is expressed by the patient, whereby a T-cell response to mesothelin is induced, wherein the epitope is selected from the group consisting of: SLLFLLFSL (SEQ ID NO: 1); VLPLTVAEV (SEQ ID NO: 2); ELAVALAQK (SEQ ID NO: 3); ALQGGGPPY (SEQ ID NO: 4); FYPGYLCSL (SEQ ID NO: 5); and LYPKARLAF (SEQ ID NO: 6).

27.-37. (Cancelled)

38. (Currently amended) ~~The method of claim 22~~ A method of inducing a T-cell response to a pancreatic tumor which overexpresses mesothelin relative to normal tissue from which it is derived, said method comprising:

administering to a patient who has said tumor or who has had said tumor removed, a composition comprising a *Listeria monocytogenes* bacterium which expresses a polypeptide comprising an MHC Class I-binding epitope of mesothelin, wherein the epitope binds to an allelic form of MHC class I which is expressed by the patient, whereby a T-cell response to mesothelin is induced, wherein the composition is administered in sufficient amount to keep the patient tumor-free greater than 60 months in patients who exhibit an increase in delayed type hypersensitivity to autologous tumor cells after administration of the composition.

39-114. (Cancelled)

115. (Currently amended) ~~The method of claim 22~~ A method of inducing a T-cell response to a tumor which overexpresses mesothelin relative to normal tissue from which it is derived, said method comprising:

administering to a patient who has said tumor or who has had said tumor removed, a composition comprising a *Listeria monocytogenes* bacterium which expresses a polypeptide comprising an MHC Class I-binding epitope of mesothelin, wherein the epitope binds to an allelic form of MHC class I which is expressed by the patient, whereby a T-cell response to mesothelin is induced, wherein the polypeptide comprises epitopes SLLFLLFSL (SEQ ID NO: 1); VLPLTVAEV (SEQ ID NO: 2); ELAVALAQK (SEQ ID NO: 3); ALQGGGPPY (SEQ ID NO: 4); FYPGYLCSL (SEQ ID NO: 5); and LYPKARLAF (SEQ ID NO: 6).

116-121. (Cancelled)